Skip to main content
MedPathMedPath Home
Clinical Trials/2023-507377-17-00
2023-507377-17-00
Recruiting
Phase 1

A Phase 1b, Randomized, Open-Label Trial to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB097 in Combination with Pembrolizumab in Melanoma Patients with Primary Resistance to an Anti-PD-1-Containing Immunotherapy (MELODY-1)

Microbiotica Limited12 sites in 3 countries27 target enrollmentJuly 22, 2024
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Microbiotica Limited
Enrollment
27
Locations
12
Status
Recruiting
Last Updated
12 months ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
euclinicaltrials.eu
Start Date
July 22, 2024
End Date
TBD
Last Updated
12 months ago

Investigators

Sponsor
Microbiotica Limited
Responsible Party
Principal Investigator
Principal Investigator

Microbiotica Information

Scientific

Microbiotica Limited

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Study Sites (12)

Loading locations...

Similar Trials

Active, Not Recruiting
Phase 1
Clinical trial with MBK-01, intestinal microbiota capsules, for the treatment of patients with recurring diverticulitis
CTIS2023-506224-87-00Mikrobiomik Healthcare Company S.L.81
Active, Not Recruiting
Phase 1
A Phase IIIb, randomised, open label study to compare the safety, efficacy and tolerability of anagrelide hydrochloride versus hydroxyurea in high-risk essential thrombocythaemia patients.Essential thrombocythaemia (ET)MedDRA version: 7.1Level: LLTClassification code 10015493
EUCTR2004-004061-15-ESShire Pharmaceutical Development Ltd.146
Active, Not Recruiting
Phase 1
A Phase IIIb, randomised, open label study to compare the safety, efficacy and tolerability of anagrelide hydrochloride versus hydroxyurea in high-risk essential thrombocythaemia patients.Essential thrombocythaemia (ET)MedDRA version: 7.1Level: LLTClassification code 10015493
EUCTR2004-004061-15-IEShire Pharmaceutical Development Ltd.184
Active, Not Recruiting
N/A
A Phase IIIb, randomised, open label study to compare the safety, efficacy and tolerability of anagrelide hydrochloride versus hydroxyurea in high-risk essential thrombocythaemia patients.Essential thrombocythaemiaMedDRA version: 12.0Level: LLTClassification code 10015493Term: Essential thrombocythaemia
EUCTR2004-004061-15-PLShire Pharmaceutical Development Ltd.184
Active, Not Recruiting
Phase 1
A Phase IIIb, randomised, open label study to compare the safety, efficacy and tolerability of anagrelide hydrochloride versus hydroxyurea in high-risk essential thrombocythaemia patients.
EUCTR2004-004061-15-BEShire Pharmaceutical Development Ltd.146